FDA Approves New Version of OTC Primatene Mist

Share this content:
FDA Approves New Version of OTC Primatene Mist
FDA Approves New Version of OTC Primatene Mist

THURSDAY, Nov. 8, 2018 (HealthDay News) -- A new version of an over-the-counter asthma inhaler that was taken off the market in 2011 has been approved by the U.S. Food and Drug Administration.

U.S. sales of Primatene Mist were halted because it contained chlorofluorocarbon propellants, which deplete the ozone layer. The new version contains hydrofluoroalkane propellants, which are permitted under international and U.S. law. Prescription inhalers also use hydrofluoroalkane propellants.

Primatene Mist is the only nonprescription metered-dose inhaler available in the United States and is approved to provide temporary relief for symptoms of mild, intermittent asthma, the FDA said. Patients with severe asthma should not rely on this inhaler, it warned.

Primatene Mist is approved only for patients who have been diagnosed with asthma by a health care provider and is not a replacement for prescription asthma treatments, the FDA said.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »